Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura J Esserman

Showing results (281-290 of 308) with videos related to

Pageof 31
Sort By:
Journal of the National Cancer Institute|June 22, 2026
Comparative 10-year performance of mammography artificial intelligence, polygenic, and clinical breast cancer risk models in the Kaiser Permanente Research BankVignesh A Arasu, Tejomay Gadgil, Joseph H Rothstein, et al.
JAMA Surgery|September 7, 2022
Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 TrialMarie Osdoit, Christina Yau, W Fraser Symmans, et al.
JAMA Internal Medicine|December 12, 2025
Germline Pathogenic Variants Among Women Without a History of Breast Cancer: A Secondary Analysis of the WISDOM Randomized Clinical TrialKirkpatrick B Fergus, Katherine S Ross, Maren T Scheuner, et al.
Annals of Surgical Oncology|August 23, 2025
ASO Visual Abstract: Impact of Neoadjuvant Chemotherapy on Surgical Outcomes and Conversion to Node-Negativity in Invasive Lobular Breast Cancer: Analysis of Molecularly High-Risk Tumors by Histologic Subtype on the I-SPY2 Clinical TrialRita A Mukhtar, Katrina Dimitroff, Christina Yau, et al.
NPJ Breast Cancer|August 23, 2018
Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response EndpointJudy C Boughey, Michael D Alvarado, Rachael B Lancaster, et al.
Annals of Surgical Oncology|June 28, 2023
Changes in Surgical Management of the Axilla Over 11 Years - Report on More Than 1500 Breast Cancer Patients Treated with Neoadjuvant Chemotherapy on the Prospective I-SPY2 TrialJudy C Boughey, Hongmei Yu, Catherine Lu Dugan, et al.
JAMA|December 12, 2025
Risk-Based vs Annual Breast Cancer Screening: The WISDOM Randomized Clinical TrialLaura J Esserman, Allison S Fiscalini, Arash Naeim, et al.
JAMA Network Open|December 28, 2023
Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast CancerBeverly Kyalwazi, Christina Yau, Michael J Campbell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2015
The Neoadjuvant Model Is Still the Future for Drug Development in Breast CancerAngela DeMichele, Douglas Yee, Donald A Berry, et al.
JAMA Oncology|February 14, 2020
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 TrialRita Nanda, Minetta C Liu, Christina Yau, et al.
Pageof 31

Showing results (281-290 of 308) with videos related to

Sort By:
Pageof 31
Journal of the National Cancer Institute|June 22, 2026
Comparative 10-year performance of mammography artificial intelligence, polygenic, and clinical breast cancer risk models in the Kaiser Permanente Research BankVignesh A Arasu, Tejomay Gadgil, Joseph H Rothstein, et al.
JAMA Surgery|September 7, 2022
Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 TrialMarie Osdoit, Christina Yau, W Fraser Symmans, et al.
JAMA Internal Medicine|December 12, 2025
Germline Pathogenic Variants Among Women Without a History of Breast Cancer: A Secondary Analysis of the WISDOM Randomized Clinical TrialKirkpatrick B Fergus, Katherine S Ross, Maren T Scheuner, et al.
Annals of Surgical Oncology|August 23, 2025
ASO Visual Abstract: Impact of Neoadjuvant Chemotherapy on Surgical Outcomes and Conversion to Node-Negativity in Invasive Lobular Breast Cancer: Analysis of Molecularly High-Risk Tumors by Histologic Subtype on the I-SPY2 Clinical TrialRita A Mukhtar, Katrina Dimitroff, Christina Yau, et al.
NPJ Breast Cancer|August 23, 2018
Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response EndpointJudy C Boughey, Michael D Alvarado, Rachael B Lancaster, et al.
Annals of Surgical Oncology|June 28, 2023
Changes in Surgical Management of the Axilla Over 11 Years - Report on More Than 1500 Breast Cancer Patients Treated with Neoadjuvant Chemotherapy on the Prospective I-SPY2 TrialJudy C Boughey, Hongmei Yu, Catherine Lu Dugan, et al.
JAMA|December 12, 2025
Risk-Based vs Annual Breast Cancer Screening: The WISDOM Randomized Clinical TrialLaura J Esserman, Allison S Fiscalini, Arash Naeim, et al.
JAMA Network Open|December 28, 2023
Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast CancerBeverly Kyalwazi, Christina Yau, Michael J Campbell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2015
The Neoadjuvant Model Is Still the Future for Drug Development in Breast CancerAngela DeMichele, Douglas Yee, Donald A Berry, et al.
JAMA Oncology|February 14, 2020
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 TrialRita Nanda, Minetta C Liu, Christina Yau, et al.
Pageof 31